Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 11 of 116

  1. Durvalumab

    AstraZeneca

    Hepatocellular Carcinoma

    phase 3 small molecule active

    2 trials

  2. Durvalumab

    AstraZeneca

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    2 trials

  3. Durvalumab

    Arcus Biosciences

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  4. Durvalumab

    AstraZeneca

    Muscle Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  5. Durvalumab

    AstraZeneca

    Advanced Hepatocellular Carcinoma

    phase 3 small molecule active

    1 trial

  6. Durvalumab

    AstraZeneca

    Cancer

    phase 3 small molecule active

    1 trial

  7. Durvalumab + SoC chemotherapy

    AstraZeneca

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule completed

    1 trial

  8. E7777 9 mcg/kg

    CITIUS ONCOLOGY, INC.

    Persistent or Recurrent Cutaneous T-Cell Lymphoma

    phase 3 small molecule completed

    1 trial

  9. EADM

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Carcinoma, Hepatocellular

    phase 3 small molecule active

    1 trial

  10. EFC10261

    Regeneron UK Limited

    Carcinoma

    phase 3 small molecule completed

    1 trial

  11. EFC10547

    Regeneron UK Limited

    Pancreatic Neoplasm

    phase 3 small molecule terminated

    1 trial

  12. EFC12522

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 3 small molecule active

    1 trial

  13. EFC15858

    Sanofi-aventis Healthcare Pty Ltd

    Non-small cell lung cancer metastatic

    phase 3 other active

    1 trial

  14. EFC15951

    Sanofi-aventis Healthcare Pty Ltd

    Cancer - Plasma cell myeloma recurrent

    phase 3 small molecule active

    1 trial

  15. EFC6125

    Regeneron UK Limited

    Ovarian Neoplasms

    phase 3 small molecule completed

    2 trials

  16. EIK1001

    Eikon Therapeutics

    Advanced Melanoma

    phase 3 small molecule active

    1 trial

  17. EIK1001

    Eikon Therapeutics

    Non Small Cell Lung Cancer (Squamous or Non Squamous)

    phase 3 small molecule active

    1 trial

  18. EIK1001-006

    Eikon Therapeutics

    Advanced Melanoma

    phase 3 small molecule active

    1 trial

  19. EMERALD-1

    AstraZeneca AB

    Locoregional Hepatocellular Carcinoma (HCC)

    phase 3 small molecule active

    1 trial

  20. ENCITJ-GC01

    Eastern Hepatobiliary Surgery Hospital

    Gastric Cancer

    phase 3 small molecule terminated

    1 trial

  21. ENGIC 06 FRUQUITAS

    CERO THERAPEUTICS HOLDINGS, INC.

    metastatic oeso-gastric adenocarcinoma

    phase 3 small molecule active

    1 trial

  22. EORTC-2238-GUCG

    Ningbo Cancer Hospital

    Metastatic hormone naïve prostate cancer (mHNPC)

    phase 3 small molecule active

    1 trial

  23. ERYTHROPOIETIN , Elritercept

    Takeda

    Myelodysplastic neoplasms/syndromes (MDS)

    phase 3 small molecule active

    1 trial

  24. ETOP25-23 ADOPT-lung

    Partner Therapeutics Limited

    Stage IIB-IIIB (N2) resectable non small cell lung cancer

    phase 3 small molecule active

    1 trial

  25. ETOPOSIDE - Usual

    Lxo Ireland Designated Activity Company

    Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  26. Elective nodal irradiation (ENI)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Esophageal Squamous Cell Carcinoma

    phase 3 other active

    1 trial

  27. Endoscopic submucosal dissection

    Chinese University of Hong Kong

    Colorectal Neoplasms

    phase 3 other active

    1 trial

  28. Endoscopic submucosal dissection

    United Therapeutics Europe Ltd

    Colorectal Neoplasms

    phase 3 other active

    1 trial

  29. Endostar

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  30. Enzalutamide

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Metastatic Hormone Sensitive Prostate Cancer

    phase 3 small molecule active

    1 trial

  31. Epinephrine

    Chinese University of Hong Kong

    Gastric Neoplasm

    phase 3 small molecule completed

    1 trial

  32. Epirubicin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma

    phase 3 small molecule active

    1 trial

  33. Eribulin Mesylate

    United Therapeutics Europe Ltd

    Breast Adenocarcinoma

    phase 3 small molecule on hold

    1 trial

  34. EstroTep 500 MBq/mL, solution injectable

    The George Institute

    Women with ER+ HER2- metastatic breast cancer who progressed on first line therapy with CDK4/6 inhibitor and aromatase inhibitor

    phase 3 small molecule active

    1 trial

  35. Etoposide

    The First People's Hospital of Lianyungang

    Non-Hodgkin's Lymphoma

    phase 3 small molecule active

    1 trial

  36. Everolimus

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  37. Evorpacept (ALX148)

    ALX ONCOLOGY HOLDINGS INC

    Gastric Cancer

    phase 3 small molecule active

    1 trial

  38. FE 999326

    Ferring Pharmaceuticals

    Bladder Cancer

    phase 3 small molecule active

    1 trial

  39. FIL_FOLL19

    Fondazione Telethon ETS

    Follicular Lymphoma

    phase 3 small molecule active

    1 trial

  40. FIL_Renoir12

    Fondazione Telethon ETS

    Follicular lymphoma

    phase 3 small molecule active

    1 trial

  41. FKB238 (bevacizumab)

    Centus Biotherapeutics Europe Limited

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule completed

    1 trial

  42. FLUOROURACIL for Rectal cancer

    Disc Medicine

    Rectal cancer

    phase 3 small molecule active

    1 trial

  43. FM-17-B01

    Fondazione Telethon ETS

    Invasive Breast Cancer

    phase 3 small molecule active

    1 trial

  44. FUNGEMAX

    CERO THERAPEUTICS HOLDINGS, INC.

    Metastatic pancreatic cancer

    phase 3 small molecule active

    1 trial

  45. FURMO-006

    ArriVent BioPharma

    Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

    phase 3 small molecule active

    1 trial

  46. FUROSEMIDE , DULOXETINE

    Ningbo Cancer Hospital

    ER positive HER2 negative breast cancer stages I-II

    phase 3 small molecule active

    1 trial

  47. Faceptor

    Biotech Pharmaceutical Co.,

    Breast Cancer Metastatic

    phase 3 small molecule completed

    2 trials

  48. Farletuzumab

    United Therapeutics Europe Ltd

    Ovarian Cancer

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.